Gero raises $17 million, bringing total equity funding to $34 million

Corporate Action
โดย Business Wire·Read original
Summary · why it matters

Gero, a physics-first AI drug discovery company focused on aging, announced $17 million in new financing, bringing its total equity funding to $34 million. The company previously secured a collaboration with Chugai Pharmaceutical, a member of the Roche Group, which includes an upfront payment and up to $250 million in milestones plus royalties. Gero uses a physics-based framework and AI trained on approximately 10 million curated longitudinal medical records to identify therapeutic targets that slow aging and treat age-related diseases. The new funding will support preclinical development of its pipeline and expansion of pharmaceutical partnerships, with participation from Melnichek Investments and other investors from the AI and pharma sectors.

Impact on stocks 2

Biotech & Genomic Medicine▲ · 1 stocks
Chugai Pharmaceutical Co., Ltd.
4519
▲ PositiveCapitalrelevance

Gero's funding and partnership with Chugai may enhance its pipeline, but Chugai is only mentioned as a collaborator, not the subject.

Health Care▲ · 1 stocks

Theme Impact 2

Off-coverage companies 2

GeroPrivate▲ Positive
Capitalrelevance

Gero raised $17 million in new financing, bringing total equity to $34 million, supporting preclinical development and partnerships.

Melnichek Investments LtdPrivate± Mixed
relevance

Related news

▲

Genflow trial hits endpoint; 80 Mile agrees takeover

Genflow Biosciences announced that its SLAB gene therapy trial in ageing dogs has met its primary endpoint, and it is now in talks with major animal health companies about a licensing deal. EnergyPathways has appointed Jacobs as engineering and regulatory partner for its MESH energy storage project in the Irish Sea, moving toward a key Ofgem funding submission. Itaconix is targeting a doubling of revenue to $30 million in the medium term, after half-year revenue jumped 72% on strong detergent demand. Gaming Realms says it is well placed to keep growing despite a UK tax hike hitting margins, with core content licensing revenue up 12% in the first half. Total Graphite reports that fresh drilling in Madagascar has strengthened the case for restarting mining at Vatomina, with one hole returning 19 metres at 3.3% graphite. 80 Mile has agreed indicative terms for a £61.5 million all-share takeover by Nasdaq-listed Greenland Energy, representing a near-47% premium to its share price.
80M.LSE ▲GENF.LSE ▲ITX.LSE ▲GLND ▲GMR.LSE EPP.LSE
Longevity & Life Extension ▲Critical Materials & Supply Chain ▲
Yahoo Finance·11dRead more →

Insilico Medicine Launches Virtual Aging Cell Platform

Insilico Medicine has launched its Virtual Aging Cell webpage and previewed a multi-agent driven platform that uses biological age as a core condition for simulating cellular dynamics. The platform deploys agent swarms across six biological scales—molecular, intracellular, intercellular, tissue, organ, and organism—to model differentiation, reprogramming, and aging, aiming to support target identification and drug discovery. The launch follows a decade of work including the PreciousGPT model series, with the company noting it has nominated 33 preclinical candidates since 2021, 13 of which have received IND approvals or clearances. Insilico will present further details at the ARDD 2026 conference in Boston.
3696.HK ▲
Biotech & Genomic Medicine Longevity & Life Extension Artificial Intelligence
PR Newswire·35dRead more →

Life Biosciences appoints Stephen Webster to board of directors

Life Biosciences has appointed Stephen Webster to its board of directors, effective August 1, 2026. Webster is a biotechnology executive who has served as chief financial officer of three public companies and played a key role in multiple financings, commercial launches, and acquisitions. He previously led approximately $1 billion in equity financings at Spark Therapeutics, oversaw its 2015 initial public offering, supported the commercial launch of LUXTURNA, and helped lead the company's $4.3 billion acquisition by Roche. Life Biosciences is a clinical-stage biotechnology company pioneering cellular rejuvenation medicines to reverse diseases of aging, with a lead program in development for optic neuropathies.
ROP.SW
Longevity & Life Extension
GlobeNewswire·39dRead more →
© 2026 MarketDXNews